OpenEvidence Secures $250M to Expand AI-Powered Clinical Search Platform

OpenEvidence, a U.S.-based healthcare technology company, has raised $250 million in a Series D funding round led by Thrive Capital and DST Global, the company announced. The investment, completed in the United States, is intended to support the expansion of its AI-powered clinical search platform as healthcare professionals face growing challenges in managing and interpreting medical information.

Thrive Capital and DST Global lead $250M bet on AI-driven clinical search

The Series D round was co-led by Thrive Capital and DST Global, two firms known for backing technology companies at later growth stages. OpenEvidence stated that existing investors also participated, signaling continued confidence in the company’s long-term strategy and product direction. The size of the round places it among the larger recent investments in the digital health and medical AI sector.

According to the company, the new funding will be used to scale its core platform, invest in research and development, and grow its engineering and clinical teams. A portion of the capital is also expected to support infrastructure improvements to ensure the platform can handle increasing usage from healthcare providers across hospitals, clinics, and academic institutions.

OpenEvidence’s product is designed to help clinicians quickly find evidence-based answers to medical questions by analyzing peer-reviewed literature, clinical guidelines, and other trusted sources. Instead of relying on general-purpose search engines, users can query the system using clinical language and receive summarized, source-linked results. The company says this approach is intended to reduce time spent searching for information while improving clinical decision-making.

Executives at OpenEvidence noted that the funding will also allow the company to strengthen partnerships with medical institutions and publishers. By expanding access to high-quality, curated content, the company aims to maintain accuracy and transparency, two critical factors for adoption in healthcare settings. Thrive Capital and DST Global, in separate statements cited by the company, emphasized the importance of tools that help clinicians manage information overload without replacing professional judgment.

AI in healthcare: balancing innovation with accuracy and trust

OpenEvidence was founded by a team with experience in medicine, data science, and artificial intelligence, with the goal of addressing a persistent challenge in healthcare: keeping up with rapidly expanding medical knowledge. Thousands of medical papers are published each week, making it increasingly difficult for clinicians to stay current while managing heavy patient workloads.

The company positions its platform as a decision-support tool rather than a diagnostic system. It does not provide medical advice directly to patients, focusing instead on assisting licensed professionals. This positioning aligns with regulatory expectations and has helped OpenEvidence integrate into clinical workflows more smoothly than consumer-facing health AI tools.

The broader market for AI in healthcare has attracted substantial investment over the past several years. Investors have shown particular interest in applications that improve efficiency, reduce administrative burden, and support evidence-based care. At the same time, the sector faces scrutiny over data privacy, model transparency, and the risk of errors. OpenEvidence has stated that it prioritizes verifiable sources and clear citations to address these concerns.

OpenEvidence’s $250 million Series D round marks a significant milestone for the company and reflects continued investor confidence in medical AI tools focused on clinical support. With backing from Thrive Capital and DST Global, OpenEvidence plans to scale its platform while maintaining an emphasis on accuracy and responsible use. As healthcare systems continue to seek ways to manage growing information demands, the company’s next phase of growth will likely be closely watched by both investors and clinicians.